Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer

Basit Öğe Kaydı
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authoridCicin, Irfan/0000-0002-7584-3868;
dc.authorwosidCosar, Rusen/GQP-7875-2022
dc.authorwosidCosar, Rusen/AAC-4045-2020
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.contributor.authorCicin, Irfan
dc.contributor.authorKaragol, Hakan
dc.contributor.authorUsta, Ufuk
dc.contributor.authorSezer, Atakan
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorAlas-Cosar, Rusen
dc.contributor.authorYetisyigit, Tarkan
dc.date.accessioned2024-06-12T10:55:15Z
dc.date.available2024-06-12T10:55:15Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study is to reveal likely demographic, clinical, and pathological differences among hormone receptor negative breast cancer patients according to their HER-2 status. The medical records of hormone receptor negative breast cancer patients with known HER-2 status between January 1999 and December 2006 were reviewed, retrospectively. A total of 91 cases were included in the study (68 HER-2 negative cases and 23 HER-2 positive cases). The results obtained showed that median age, menarche age, childbearing age, number of children, menopause age, and body-mass indexes were similar in both groups. The HER-2 negative patients had more family history of breast cancer than HER-2 positive patients (13.2% and 0%, respectively, P = 0.091). Eighty-three patients received neoadjuvant/adjuvant chemotherapy. Recurrence occurred in 41 (46.6%) patients. Neither recurrence nor disease-free survival of those patients was associated with HER-2 status. Tumor size (P = 0.042) and number of involved lymph nodes (P = 0.001) were found to be independent prognostic factors for disease-free survival. A tendency for more frequent cerebral metastasis was found in HER-2 positive advanced stage patients (P = 0.052). HER-2 positive patients were less responsive to taxanes (P = 0.071). The number of involved lymph nodes (P = 0.004) and HER-2 status (P = 0.043) were found to be prognostic factors for overall survival. HER-2 positive and negative patients should be followed and treated with different strategies. HER-2 positive patients are at least as resistant to systemic therapies as the HER-2 negative patients. Genetic counseling should be routinely provided to triple negative patients and their families. HER-2 positive patients may be candidates for prophylactic treatment strategies concerning cerebral metastasis.en_US
dc.identifier.doi10.1007/s12032-008-9126-3
dc.identifier.endpage343en_US
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue3en_US
dc.identifier.pmid19003545en_US
dc.identifier.scopus2-s2.0-77954082807en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage335en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-008-9126-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19357
dc.identifier.volume26en_US
dc.identifier.wosWOS:000269118000014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectTriple Negativeen_US
dc.subjectHER-2en_US
dc.subjectPrognostic-Significanceen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectSurvivalen_US
dc.subjectTrastuzumaben_US
dc.subjectOverexpressionen_US
dc.subjectAmplificationen_US
dc.subjectMetastasisen_US
dc.subjectStrategiesen_US
dc.subjectEstrogenen_US
dc.subjectSubtypesen_US
dc.titleTriple negative breast cancer compared to hormone receptor negative/HER2 positive breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu